Artisan Partners is a global investment management firm that provides a broad range of high value-added investment strategies in growing asset classes to sophisticated clients around the world. Since 1994, the firm has been committed to attracting experienced, disciplined investment professionals to manage client assets. Artisan Partners’ autonomous investment teams oversee a diverse range of investment strategies across multiple asset classes. Strategies are offered through various investment vehicles to accommodate a broad range of client mandates.
This site is intended for use with US institutional investors which includes corporate and public retirement plans, foundations, endowments, trusts and their consultants. Note: This account is not managed or monitored by Artisan Partners, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use the firm’s official channels.

Shares of Colgate-Palmolive slipped 2.35% on Tuesday following its Investor Day 2026 presentation. Investors appeared cautious as management outlined strategic priorities that balance aggressive brand investments with long-term profitability goals, causing the stock to slide to an intra-day low of Rs 1,965 on the BSE.

Should you buy, sell or hold the stock?

In an analyst note reported by ET Now, Goldman Sachs maintained its Neutral rating on Colgate Palmolive with a target price of Rs 2,050, implying a modest upside from current levels. The brokerage highlighted that Colgate’s strategy is aggressively pivoting toward volume recovery, premiumization, and category expansion. ET Now reported that while heavy step-ups in brand spending and advertising intensity could weigh on operational margins over the short term, structural cost savings from the company’s ‘Funding the Growth’ initiative will help cushion profitability.
Motilal Oswal maintained its Buy rating on Colgate Palmolive with a target price of Rs 2,500, implying a 27% upside from current levels. The brokerage noted that the core investment thesis remains intact as Colgate continues to lead and drive category expansion in India. It highlighted strong traction in science-led innovations like Colgate Strong Teeth with Arginine and rapid scaling in premium offerings such as Visible White Purple. Motilal Oswal expects sales to reach Rs 66.5 billion in FY27E and Rs 71.2 billion in FY28E, supported by steady volume execution and segment leadership.

Nuvama maintained its Buy rating on Colgate Palmolive with a target price of Rs 2,350, implying a 22.5% upside from current levels. The brokerage highlighted the company’s persistent focus on driving oral care penetration and expanding market reach. It noted that 45% of rural Indians still do not brush daily and 76% of urban Indians do not brush twice a day. Nuvama added that management’s decision to allocate roughly 16% of revenues toward brand building underscores a strategy centred on long-term category expansion over short-term margin maximisation, backed by a distribution footprint across 7.1 million stores.

Colgate management commentary

Managing Director Prabha Narasimhan emphasised that Colgate is best placed to lead and expand the oral care category in India. “Our strategy is clear: drive growth ahead of profitability,” management stated, pointing out that premium toothpaste share has expanded 2.5 times compared to 2021 levels and direct retail coverage now reaches 1.7 million outlets.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of The Economic Times.)

Shares of Biocon rose 2% to Rs 420.25 on the BSE on Tuesday, after the company’s subsidiary in the United States received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek 90 mg/ml single-dose prefilled autoinjector.

According to a regulatory filing by the company on the BSE, the Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.

“This supplemental approval enhances Biocon’s comprehensive portfolio of immunology products in the United States and reaffirms the company’s commitment to improving access to affordable medicines for patients around the world,” the company said, as per the regulatory filing.

Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients who are six years of age and older, and moderate to severely active Crohn’s disease and ulcerative colitis in adults, thereby treating a range of debilitating autoimmune conditions that affect tens of thousands of Americans.

Biocon Q1 Results

The company reported a net profit of Rs 141 crore in the June quarter of FY27. It reported a 10% year-on-year increase in consolidated operating revenue to Rs 4,336 crore, driven by strong growth in the Biopharma business. Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.

Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%, supported by improved profitability in the Biopharma business, which helped offset continued challenges in the Services business.

Biocon Share Price

Shares of Biocon have gained nearly 3% in the last three months. However, the shares have slipped over 7% over the last six months.

The shares of the drugmaker have declined over 9% in 2026 so far. In the longer term, Biocon shares have fallen over 4% over one year, but have delivered 19% returns over three years and 39% returns over five years.

Shares of Welspun Living surged 7.77% to Rs 181.17 in Tuesday’s trading session, extending their winning streak to a third consecutive day. The stock has gained nearly 14% over the past three sessions, driven by strong investor sentiment following the company’s robust Q1FY27 performance, announced on August 13.

The home-textile major reported a strong start to FY27, with revenue growth, a sharp jump in profitability and improving operating margins strengthening the outlook for the business.

Following the strong quarterly performance, brokerages Motilal Oswal Financial Services and JM Financial retained their ‘Buy’ ratings on the stock, citing improving business fundamentals and further earnings growth potential.

Welspun Living’s consolidated profit for the June quarter jumped 85% year-on-year (YoY) to Rs 161 crore, compared with Rs 87 crore in the same quarter last year. Revenue from operations increased 24% YoY to Rs 2,795 crore, compared with Rs 2,261 crore in the year-ago period.

JM Financial maintains ‘Buy’ rating

JM Financial remains positive on Welspun Living and has maintained its ‘Buy’ rating following the company’s stronger-than-expected Q1FY27 performance.
The brokerage highlighted that consolidated EBITDA of Rs 320 crore was well ahead of its estimate of Rs 280 crore. The outperformance was supported by better operating leverage and an improved product mix. EBITDA margin expanded by 151 basis points YoY to 11.5%, pointing to an improvement in the company’s operating efficiency.Motilal Oswal sees further upside

Motilal Oswal Financial Services has also reiterated its ‘Buy’ rating on Welspun Living, with a target price of Rs 215, indicating further upside from the stock’s current levels. The brokerage expects Welspun Living to sustain double-digit revenue growth as home-textile volumes recover. It also expects EBITDA margins to move towards 13%, aided by a better business mix and a recovery in flooring margins.

Motilal Oswal expects the core home-textile business to clock around 15% CAGR between FY26 and FY28. Bath is expected to lead growth with a high-teens expansion, followed by Bed and Rugs & Carpets. The emerging business is projected to grow at around 17%.

Stock performance

Welspun Living shares have delivered a strong performance over the past year, gaining around 45%. The stock currently has a market capitalisation of approximately Rs 15,886 crore. In Tuesday’s session, the stock touched a fresh 52-week high of Rs 182, reflecting the strong momentum following the Q1 results.

Technical indicators remain positive

On the technical front, the stock’s 14-day Relative Strength Index (RSI) stood at 57.4. An RSI below 30 is generally considered to indicate an oversold zone, while a reading above 70 is considered overbought. The broader trend also remains bullish, with Welspun Living trading above all eight tracked simple moving averages (SMAs).

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

The first, MV Glen Sannox, was finally delivered in November 2024, while MV Glen Rosa is due for completion by the end of this year.

The shipyard recently completed sub-contracting work for BAE Systems for new Type 26 frigates and currently has no confirmed future orders.

In March, before the Holyrood election, the Scottish government announced plans to directly award the shipyard contracts for four future vessels.

It said the vessels – two small CalMac ferries, a fisheries research ship and a marine protection vessel – would provide a “bridge to the future” for the yard.

The then Economy Secretary Kate Forbes said the government had “done a lot of the upfront work in terms of scoping out, securing some of the legal advice about what is possible”.

But she added that engagement with the Competition and Markets Authority would be required.

Stripping out bonuses, wage growth stood at 3.5 per cent the ONS said

Wage growth surpassed expectations as pay settlements in the public sector significantly outpaced those in the private sector, according to newly released figures. Official data has revealed that wage growth, inclusive of bonuses, hit 4.1 per cent between April and June, against a market forecast of four per cent.

This nonetheless fell short of the 4.3 per cent recorded in the previous month. Stripping out bonuses, pay growth stood at 3.5 per cent, which also marginally exceeded the projections of City economists and investors.

The stronger-than-anticipated pay growth was, however, predominantly driven by the public sector. Average earnings growth reached 5.5 per cent in the public sector, compared with just 2.9 per cent in the private sector, as reported by City AM.

“The labour market picture is little changed overall, with some softening still evident,” said Liz McKeown, director of economic statistics at the ONS.

“Private sector pay growth has continued to ease, while public sector pay growth remains elevated due to the timing of the latest NHS pay awards.”

The ONS further estimated that the unemployment rate held steady at 4.9 per cent, exceeding economists’ projections.

This coincided with the number of payrolled employees rising by 3,000 between April and May, though remaining approximately 85,000 below figures recorded a year earlier.

Meanwhile, the number of vacancies fell by 6,000 to 707,000, representing its lowest point in over five years. “The latest decrease was driven mainly by smaller businesses, which cite labour and operating costs as reasons for not hiring new staff or replacing leavers,” McKeown added.

Fresh data could signal troubled times ahead for the UK economy, with the Bank of England and City economists warning that the labour market may deteriorate later this year.

The Bank has forecast the unemployment rate to reach 5.2 per cent, while more pessimistic projections place the peak closer to 5.5 per cent. Subdued wage growth and increasing unemployment could alleviate concerns that the Bank is poised to raise interest rates in response to the energy price shock stemming from ongoing trade disruption across the Middle East.

The Conservative opposition is stepping up its pressure on the Labour government over job losses.

Under a new pledge described as a “benefit of Brexit“, the party has announced it would scrap EU regulations governing young people’s capacity to work.

Rules requiring 16 and 17-year-olds to take a rest period of 48 consecutive hours in any given week would be abolished, while young people would also be permitted to work later into the night at weekends during term time and at any hour outside of term time.

Party officials stated they were drawing upon findings from the Alan Milburn review on Neets, young people not in employment, education or training. The paper by Milburn found that work for young people helped “build on confidence, learn the habits of work and show employers what they could do”, though opportunities to do so had since ended.

Shares of Tube Investments of India surged over 8% to Rs 2,952 on the BSE on Tuesday, after the company reported its earnings for the quarter ended in June 2026.

As per a regulatory filing on the BSE released on Friday, the company’s Q1 profit after tax declined over 5% year-on-year to Rs 158.62 crore, from Rs 168.09 crore in the corresponding quarter of the previous year. Revenue from operations stood at Rs 2,227.63 crore, as compared to Rs 1,892.48 crore in the same quarter last year.

What Motilal Oswal said

Domestic brokerage firm Motilal Oswal reiterated its Buy rating on the stock, with a target price of Rs 3,379, citing in-line earnings despite margin miss. Tube Investments India’s core business remains fundamentally strong, with the Engineering business having delivered 17% volume growth and exports growing in double digits, while MFP revenue growth improved to 11.5% during the quarter, the brokerage stated in its note.

Despite near-term margin headwinds, Tube Investments of India offers diversified revenue streams, with steady growth in the core business (~7% S/A PAT CAGR over FY26-28E) and CG Power, as well as the optionality of new businesses incubated under the TI-2 strategy, according to the brokerage.

Two of the standalone entity’s business segments, viz., Engineering and Metal Formed divisions, which contribute ~80% of its revenue, are dependent on the auto business, the brokerage stated. While the GST rate reduction has helped revive auto demand across segments, the near-term outlook for the sector has turned cautious given the potential impact of the ongoing geopolitical issues on the economy. Motilal Oswal expects the standalone business to post a steady CAGR of 8%/8%/7% in revenue/EBITDA/PAT over FY26-28.

Management outlook

Management remains constructive on the near-term demand environment, with strong momentum visible across most vehicle categories and geographies, as per the brokerage report. Engineering volumes and exports are expected to remain healthy over the next one to two quarters, while new product development and customer relationships provide additional growth support. Margin recovery remains a key near-term catalyst, with full recovery of steel inflation and potential recovery of other input-cost inflation expected to progressively improve profitability.
Overall, the company remains focused on scaling its core businesses while investing in medical, CDMO, EV mobility, battery manufacturing, and other emerging businesses to build multiple growth engines.